Innovating Works

THE GENERAL UNIVERSITY HOSPITAL IN PRAGU...

Desconocido
CLAIMS: CLinical impact through AI-assisted MS care VSEOBECNA FAKULTNI NEMOCNICE V PRAZE participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system. Since there is no cure available yet for MS...
2023-05-15 - 2027-05-31 | Financiado
c4c: conect4children COllaborative Network for European Clinical Trials For Children VSEOBECNA FAKULTNI NEMOCNICE V PRAZE participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado
BRCA-ERC: Understanding cancer development in BRCA 1 2 mutation carriers for improved Early detection and Risk... VSEOBECNA FAKULTNI NEMOCNICE V PRAZE participó en un H2020: ERC-2016-ADG Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largel...
2017-06-14 - 2023-05-31 | Financiado
TB and Tobacco: Tobacco cessation within TB programmes A real world solution for countries with dual burden of di... VSEOBECNA FAKULTNI NEMOCNICE V PRAZE participó en un H2020: H2020-HCO-2014-2015 We aim to reduce the burden of tobacco-related lung diseases. Our approach is to integrate inexpensive tobacco cessation strategies of prove...
2015-09-24 - 2019-10-31 | Financiado
SECURE: Secondary prEvention of CardiovascUlaR disease in the Elderly trial VSEOBECNA FAKULTNI NEMOCNICE V PRAZE participó en un H2020: H2020-PHC-2014-2015 While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overal...
2015-04-08 - 2021-12-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.